Last reviewed · How we verify
Enriched Ringer's lactate solution
Enriched Ringer's lactate solution is an intravenous fluid replacement therapy that restores electrolyte balance and provides hydration to maintain cellular and circulatory homeostasis.
Enriched Ringer's lactate solution is an intravenous fluid replacement therapy that restores electrolyte balance and provides hydration to maintain cellular and circulatory homeostasis. Used for Fluid resuscitation and volume replacement in acute blood loss or dehydration, Maintenance fluid therapy in perioperative and critical care settings, Correction of electrolyte imbalances.
At a glance
| Generic name | Enriched Ringer's lactate solution |
|---|---|
| Sponsor | Scientific Institute San Raffaele |
| Drug class | Crystalloid intravenous fluid |
| Modality | Small molecule |
| Therapeutic area | Critical Care / Fluid Management |
| Phase | FDA-approved |
Mechanism of action
This is a crystalloid solution containing sodium, potassium, calcium, chloride, and lactate ions in physiologically balanced concentrations. It is used for fluid resuscitation, maintenance of intravascular volume, and correction of electrolyte imbalances in clinical settings. The lactate component is metabolized by the liver to bicarbonate, providing mild alkalinizing effects.
Approved indications
- Fluid resuscitation and volume replacement in acute blood loss or dehydration
- Maintenance fluid therapy in perioperative and critical care settings
- Correction of electrolyte imbalances
Common side effects
- Hyperkalemia (with prolonged use or renal impairment)
- Fluid overload / pulmonary edema
- Hyponatremia (with excessive administration)
- Phlebitis at infusion site
Key clinical trials
- A Phase 2b Multi-Center, Randomized, Double-Blind, Placebo-Controlled Study, Evaluating Efficacy and Safety of Allocetra-OTS in Patients With Severe or Critical COVID-19 With Associated Acute Respiratory Distress Syndrome (ARDS) (PHASE2)
- Allocetra-OTS in COVID-19, Phase II (PHASE2)
- Allocetra-OTS in COVID-19 (PHASE1)
- Prevention of Sepsis-related Organ Dysfunction With Allocetra-OTS (PHASE1)
- CUstodiol Versus RInger: whaT Is the Best Agent? (PHASE4)
- Study of Corneas Undergoing Balanced Salt Solution(BSS ®) Versus Glucose-bicarbonate-Ringer Lactate in Cataract Surgery (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: